Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness
Claims-linked Survey Study to Assess Burden of Illness Among Patients Treated With LAMA/LABA vs ICS/LABA Single Inhaler Dual Therapy
Sponsor: GlaxoSmithKline
Listed as NCT03543176, this observational or N/A phase trial focuses on Pulmonary Disease, Chronic Obstructive and remains completed. Sponsored by GlaxoSmithKline, it has been updated 15 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Feb 2025 — Present [monthly]
Completed
-
Sep 2024 — Feb 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 10 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Sep 2020 — Nov 2020 [monthly]
Completed
-
Feb 2020 — Sep 2020 [monthly]
Completed
-
Oct 2019 — Feb 2020 [monthly]
Completed
Status: Recruiting → Completed
-
Sep 2019 — Oct 2019 [monthly]
Recruiting
-
Aug 2019 — Sep 2019 [monthly]
Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Recruiting
-
Jul 2018 — Jul 2019 [monthly]
Recruiting
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- UnitedHealth Group
For direct contact, visit the study record on ClinicalTrials.gov .